このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Frozen Section-Guided Selective Ipsilateral Central Neck Dissection in Bethesda V-VI Thyroid Nodules

2026年6月19日 更新者:Eleonora Lori, MD

Frozen Section-Guided Selective Ipsilateral Central Neck Dissection in Bethesda V-VI Thyroid Nodules: A Pilot Cohort Study Informing Surgical Extent

The goal of this observational pilot cohort study is to evaluate the feasibility and clinical implications of frozen section analysis-guided selective ipsilateral central neck dissection in adult patients undergoing primary thyroid surgery for Bethesda V-VI thyroid nodules with a clinically node-negative neck.

The main questions it aims to answer are:

  • Can intraoperative frozen section analysis of ipsilateral level VI lymph nodes meaningfully inform real-time surgical decision-making?
  • Can this strategy support tailored escalation or de-escalation of central compartment surgery while minimizing unnecessary bilateral central neck dissection and its associated morbidity? Researchers will compare patients managed with ipsilateral central neck dissection and intraoperative frozen section analysis with patients managed without frozen section analysis, in order to evaluate differences in treatment adequacy, surgical decision-making, and pathological nodal assessment.

Participants will undergo primary thyroid surgery according to institutional practice. In patients managed with the frozen section analysis-guided strategy, one or more ipsilateral level VI lymph nodes will be removed during surgery and examined intraoperatively. The result of frozen section analysis may be used to guide the extent of central compartment surgery and the overall surgical strategy.

調査の概要

詳細な説明

This observational retrospective cohort study was conducted in a tertiary referral endocrine surgery unit and was based on prospectively collected institutional data. The study included consecutive adult patients undergoing primary thyroid surgery for cytologically suspicious or malignant thyroid nodules, classified as Bethesda V or VI according to the Bethesda System for Reporting Thyroid Cytopathology.

The study was designed to evaluate whether an intraoperative strategy based on ipsilateral central neck dissection (ipsiCND) with frozen section analysis (FSA) could improve the adequacy of surgical treatment in selected patients with low-risk thyroid cancer, potentially reducing both overtreatment and undertreatment. The institutional protocol incorporating ipsiCND-FSA was introduced in September 2023. Patients treated before implementation of this protocol generally underwent total thyroidectomy according to the standard institutional practice in place at that time. After implementation of the protocol, hemithyroidectomy combined with ipsilateral central neck lymph node sampling and intraoperative frozen section analysis was systematically proposed as the preferred surgical strategy in appropriately selected patients. Total thyroidectomy remained an option for patients who declined the conservative approach after counselling regarding the malignant or suspicious nature of the thyroid nodule and the available surgical alternatives.

Eligible patients were adults aged 18 years or older with a solitary thyroid nodule measuring less than 2.5 cm in maximum diameter, classified as Bethesda V or VI on preoperative cytology, with a clinically node-negative neck documented by preoperative cervical ultrasound. Patients were considered only if they underwent primary thyroid surgery and had complete histopathological data available for the thyroid specimen and, when removed, central compartment lymph nodes. Patients with previous thyroid or neck surgery, known distant metastases at the time of surgery, incomplete clinical or pathological data relevant to the study endpoints, or reoperations such as completion thyroidectomy or secondary lymph node dissection were excluded.

All patients received detailed preoperative counselling and provided written informed consent before surgery. The information provided included the planned procedure, the possible need for intraoperative modification of the surgical strategy according to real-time findings and frozen section results, and the potential risks and benefits of the available surgical options. Patients also consented to the inclusion of their clinical and pathological data in the institutional database and to their use for research purposes. The study was conducted in accordance with the principles of the Declaration of Helsinki, followed good clinical practice standards, and was approved by the local Ethics Committee under protocol PA-1-RETRO-2026-TBD. Reporting was planned in accordance with the STROCCS recommendations for observational studies.

All surgical procedures were performed or supervised by experienced endocrine surgeons. Intraoperative nerve monitoring was routinely used in all cases as part of the standard institutional practice. The extent of thyroid surgery, either total thyroidectomy or lobectomy/isthmectomy, and the strategy for management of the central neck compartment were planned preoperatively according to cytological diagnosis, imaging findings, clinical risk profile, and institutional practice. In patients managed according to the ipsiCND-FSA protocol, the operative plan could be modified intraoperatively on the basis of frozen section findings.

Patients were stratified according to intraoperative management of the central compartment. In the FSA group, one or more ipsilateral level VI lymph nodes were removed during hemithyroidectomy and immediately submitted for frozen section analysis. Lymph nodes were processed using standard cryostat techniques, stained with hematoxylin and eosin, and evaluated intraoperatively by an experienced pathologist. The intraoperative nodal status was reported as positive or negative for metastatic disease. Definitive paraffin-embedded histopathology served as the reference standard for final assessment. In the non-FSA group, no intraoperative frozen section analysis of central compartment lymph nodes was performed. In this cohort, patients underwent total thyroidectomy, reflecting the inability to obtain sufficiently reliable preoperative risk stratification according to the standard approach used before implementation of the new protocol.

The primary objective of the study was to assess treatment adequacy. Treatment adequacy was defined as the concordance between the surgical procedure actually performed and the minimum surgical treatment considered necessary to achieve appropriate locoregional disease control on the basis of final histopathological findings. The minimum necessary extent of surgery was determined retrospectively, with particular attention to definitive tumor characteristics, including tumor focality and laterality, extrathyroidal extension, vascular invasion, aggressive histological variants, and nodal involvement.

Overtreatment was defined as performance of total thyroidectomy in patients who were ultimately found to have a solitary unilateral carcinoma without microscopic or macroscopic extrathyroidal extension, vascular invasion, or aggressive histological variants. Undertreatment was defined as an insufficient extent of surgery in the presence of adverse pathological features requiring a more comprehensive oncological procedure. These definitions were applied irrespective of study group allocation. For comparative analyses, overtreatment and undertreatment were also combined into a composite endpoint of surgical mis-treatment.

Secondary objectives included evaluation of the diagnostic performance of frozen section analysis for detecting central compartment lymph node metastases. Diagnostic performance was assessed by calculating sensitivity, specificity, positive predictive value, negative predictive value, overall accuracy, and the area under the receiver operating characteristic curve, using definitive histopathology as the reference standard. Additional secondary outcomes included postoperative complications and length of hospital stay. Postoperative complications included major complications such as recurrent laryngeal nerve injury, hypoparathyroidism, postoperative hemorrhage, and minor complications such as seroma, hematoma, and wound infection.

Clinical, surgical, pathological, and postoperative data were extracted from the prospectively maintained institutional database and cross-checked against source documents, including operative reports, pathology reports, ultrasound reports, discharge summaries, and postoperative follow-up records. Data quality was supported by predefined data fields, standardized definitions of variables and endpoints, internal consistency checks, and verification of missing or inconsistent values against the original clinical documentation. Missing data were handled by excluding patients with incomplete information relevant to the primary endpoint or key secondary endpoints. No formal sample size calculation was performed because of the retrospective observational design; all consecutive eligible patients treated between January 2023 and June 2025 were included.

Statistical analyses were planned to compare baseline characteristics, surgical management, treatment adequacy, diagnostic performance of frozen section analysis between study groups. Diagnostic performance of frozen section analysis was evaluated against definitive histopathology as the reference standard. Additional analyses were planned to account for potential confounding and to assess the robustness of the primary findings.

研究の種類

観察的

入学 (実際)

66

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Sicily
      • Palermo、Sicily、イタリア、90127
        • Policlinico "P. Giaccone" University of Palermo

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

The study population includes consecutive adult patients treated in a tertiary referral endocrine surgery unit who underwent primary thyroid surgery for cytologically suspicious or malignant thyroid nodules. Eligible patients had Bethesda V or VI thyroid cytology, a solitary low-risk thyroid nodule smaller than 2.5 cm, and a clinically node-negative neck documented by preoperative cervical ultrasound. All patients were managed according to institutional surgical protocols and had prospectively collected clinical, surgical, and histopathological data available for analysis.

説明

Inclusion Criteria:

  • age 18 years or older.
  • Adult patients undergoing primary thyroid surgery.
  • Preoperative thyroid cytology classified as Bethesda V or Bethesda VI according to the Bethesda System for Reporting Thyroid Cytopathology.
  • Presence of a solitary thyroid nodule.
  • Maximum nodule diameter less than 2.5 cm.
  • Low-risk thyroid nodule according to clinical, cytological, and ultrasound criteria.
  • Clinically node-negative neck, documented by preoperative cervical ultrasound.
  • Availability of complete histopathological report for the thyroid specimen.
  • Availability of complete histopathological report for central compartment lymph nodes, when removed.
  • Written informed consent for surgery and for the use of clinical and pathological data for research purposes.

Exclusion Criteria:

  • Age younger than 18 years.
  • Previous thyroid or neck surgery, including completion thyroidectomy or secondary lymph node dissection
  • Known cervical lymph node metastases or distant metastases at the time of surgery.
  • Thyroid nodule measuring 2.5 cm or more in maximum diameter.
  • Incomplete clinical and pathological data relevant to the study endpoints.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
non-FSA Group
Participants in the non-FSA group underwent total thyroidectomy according to the 2015 American Thyroid Association guidelines and the institutional standard practice. The surgical strategy was based on preoperative cytology, cervical ultrasound findings, clinical risk assessment, and multidisciplinary evaluation. Central compartment lymph node management was performed according to the surgeon's judgment and preoperative findings.
FSA Group
Participants in the FSA group underwent hemithyroidectomy with selective ipsilateral central neck dissection. One or more ipsilateral level VI lymph nodes were removed during surgery and submitted for intraoperative frozen section analysis (FSA). The frozen section result was used to inform real-time surgical decision-making and to guide possible escalation or de-escalation of the surgical strategy.
Frozen section analysis (FSA) is an intraoperative pathological technique used to provide a rapid assessment of excised tissue during surgery. In this study, ipsilateral level VI lymph nodes were removed and immediately sent to the pathology department, where they were frozen, sectioned using standard cryostat techniques, stained with hematoxylin and eosin, and examined by an experienced pathologist. The result was reported intraoperatively as positive or negative for lymph node metastasis and used to support real-time surgical decision-making.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Treatment adequacy
時間枠:From surgery to availability of final histopathological report, approximately 2-4 weeks after surgery.
concordance between the surgical procedure performed and the minimum surgical treatment considered necessary for appropriate locoregional disease control, as determined retrospectively on the basis of final histopathological findings. Surgical treatment will be classified as adequate, overtreatment, or undertreatment. Overtreatment is defined as total thyroidectomy in patients ultimately found to have a solitary unilateral carcinoma without adverse pathological features. Undertreatment is defined as an insufficient surgical extent in the presence of adverse pathological features requiring a more comprehensive oncological procedure.
From surgery to availability of final histopathological report, approximately 2-4 weeks after surgery.

二次結果の測定

結果測定
メジャーの説明
時間枠
Length of hospital stay
時間枠:From surgery to hospital discharge, usually within 1-3 days after surgery.
Length of hospital stay will be measured as the number of days from the date of surgery to the date of hospital discharge.
From surgery to hospital discharge, usually within 1-3 days after surgery.
Complications
時間枠:From surgery to postoperative follow-up, approximately 30-60 days after surgery.
Complications will be assessed after thyroid surgery and classified as major or minor. Major complications include recurrent laryngeal nerve injury, hypoparathyroidism, and postoperative haemorrhage. Minor complications include seroma, haematoma, and wound infection.
From surgery to postoperative follow-up, approximately 30-60 days after surgery.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Gregorio Scerrino, MD、Policlinico "P. Giaccone" University of Palermo

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年1月9日

一次修了 (実際)

2025年6月27日

研究の完了 (実際)

2025年9月19日

試験登録日

最初に提出

2026年6月15日

QC基準を満たした最初の提出物

2026年6月15日

最初の投稿 (実際)

2026年6月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月24日

QC基準を満たした最後の更新が送信されました

2026年6月19日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be made available to other researchers. The study is based on institutional clinical and pathological data collected during routine care, and data sharing is restricted by privacy regulations and institutional policies. Only aggregate and anonymized data supporting the results may be reported in the final manuscript and related publications.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する